A recurring consumable model and expanding automated-delivery adoption can support durable per-share growth. Q2 revenue rose 23.5% to $801.7 million, including strong international growth. The key question is whether new-patient adoption, retention and manufacturing scale sustain attractive margins as competition increases. The lower market valuation improves the entry case, provided the operating thesis remains intact. The latest call exposed weaker Type 2 retention, rather than merely slightly lower utilization. Management's revised guidance assumes those trends persist through the second half. Faster new-patient starts cannot compensate indefinitely for patients leaving treatment.

What the Market May Be Mispricing

Debate	Research judgment
New-patient starts and retention	A recurring consumable model and expanding automated-delivery adoption can support durable per-share growth.
Reimbursement, competition and product reliability	New-patient starts, retention, pods per active user, reimbursement and manufacturing yields determine lifetime value.
Manufacturing scale and cash conversion	Q2 GAAP operating margin was 16.2%, while adjusted margin was 19.3%.

Insulet sells Omnipod tubeless insulin-delivery systems, with recurring disposable pods supporting revenue after a patient adopts the platform. Automated delivery integrates with compatible glucose-monitoring technology and software. Pharmacy distribution, reimbursement, clinical support and patient training shape access. U.S. and international adoption have different pricing and reimbursement economics.

Business Takeaway

Insulet sells Omnipod tubeless insulin-delivery systems, with recurring disposable pods supporting revenue after a patient adopts the platform. New-patient starts, retention, pods per active user, reimbursement and manufacturing yields determine lifetime value.

Insulin-treated diabetes provides a meaningful runway, including patients who have not used pumps. Clinical eligibility, reimbursement, patient preference and training constrain the economically reachable market. Competing delivery systems and improving therapies can change adoption, but should be evaluated using actual patient and clinical evidence.

Market-Share Analysis

Comparable same-definition share data for the subject and its principal rivals were not established. TAM estimates and company-specific volume measures are not treated as directly comparable market shares. The positioning analysis below is more reliable than a table of unmatched percentages.

Competitive Scale / Position

Company / Platform	Primary Position	Relative Scale	Growth Direction	Investment Relevance
Tandem (TNDM)	Direct: insulin pumps and automated insulin delivery	Product scope; no matched operating-scale series	Competes for pump starts and renewals	Customer choice in the stated segment only
Beta Bionics (BBNX)	Direct: iLet automated insulin delivery	Product scope; no matched operating-scale series	Competes for AID patient adoption	Customer choice in the stated segment only
MiniMed (MMED)	Direct: MiniMed automated insulin-delivery systems	Product scope; no matched operating-scale series	Competes for AID patients	Customer choice in the stated segment only
Multiple daily injections	Substitute: insulin pens/syringes, often with CGM	Product scope; no matched operating-scale series	Patient preference and access affect substitution	Customer choice in the stated segment only

Industry Takeaway

Competing delivery systems and improving therapies can change adoption, but should be evaluated using actual patient and clinical evidence. The base case requires evidence of profitable adoption within that market.

Competitive Landscape

Pump/AID systems and injections are the relevant alternatives. Dexcom supplies complementary glucose data and is not a pump competitor. Use independent MiniMed rather than the former Medtronic parent after separation.

Competitor	Market Share	Positioning	Advantages vs. Company	Disadvantages vs. Company	Current Direction
Tandem (TNDM)	No consistent comparable series	Direct: insulin pumps and automated insulin delivery	Established pump/algorithm ecosystem	Tubed/tubeless workflows and distribution differ	Competes for pump starts and renewals
Beta Bionics (BBNX)	No consistent comparable series	Direct: iLet automated insulin delivery	Distinct automation proposition	Different device workflow and commercial scale	Competes for AID patient adoption
MiniMed (MMED)	No consistent comparable series	Direct: MiniMed automated insulin-delivery systems	Pump, sensor and consumables ecosystem	Independent after Medtronic separation; distinct tubed workflow	Competes for AID patients
Multiple daily injections	No consistent comparable series	Substitute: insulin pens/syringes, often with CGM	Familiar treatment and no pump attachment	Does not provide the same automated delivery workflow	Patient preference and access affect substitution

Moat Assessment

Tubeless design, regulatory approvals, patient familiarity, distribution and integration create strong switching costs and differentiation. Competition can still improve convenience or pricing. The moat depends on maintaining reliability and patient outcomes.

Moat direction: Stable — an analytical judgment about product and distribution economics, not a measured market-share claim.

Competitive Takeaway

Tubeless design, regulatory approvals, patient familiarity, distribution and integration create strong switching costs and differentiation. The direct rivals determine commercial pressure; diversified or sector anchors provide valuation context and are not substitutes for direct competition.

Historical Financials

Financial reporting periods follow the issuer's fiscal year: completed FY rows plus standalone current-year quarters and cumulative H1/9M for FY2026. Revenue, FCF and SBC are flows; cash is a period-end balance. FCF = operating cash flow minus property/equipment capex from SEC company facts; quarterly FCF after Q1 and any quarterly SBC derived from YTD are visibly marked. Missing values are N/D, not zero. Unit: USD millions. Data extracted from SEC-tagged filings as of 2026-11-07. Company-specific FCF definitions and acquisition effects may require further reconciliation.

Period	Revenue	Growth	Gross Margin	Operating Margin	FCF	FCF Margin	SBC	Diluted Shares	Cash	Debt
FY2024	2,072	22.07%	69.79%	14.91%	305.3	14.74%	69.3	74	958.8	1,434
FY2025	2,708	30.73%	71.63%	17.50%	377.7	13.95%	62.7	72	716.1	1,003
Q1 FY2026	$761.7	N/D	69.5%	16.0%	$89.5 (derived: CFO - capex)	11.8%	$21.3	70.202	N/D	N/D
Q2 FY2026	$801.7	N/D	70.2%	16.2%	$55.9 (derived: current YTD - prior YTD)	7.0%	$19.6 (derived: current YTD - prior YTD)	69.403	N/D	N/D
H1 FY2026	$1,563.4	N/D	69.8%	16.1%	$145.4 (derived: CFO - capex)	9.3%	$40.9	69.803	N/D	N/D
Q3 FY2026	$842	N/D	75.1%	22.5%	$66.4 (derived: current YTD - prior YTD)	7.9%	$20.6 (derived: current YTD - prior YTD)	69.492	N/D	N/D
9M FY2026	$2,405.4	N/D	71.7%	18.4%	$211.8 (derived: CFO - capex)	8.8%	$61.5	69.699	N/D	N/D

Financial Takeaways

Q2 GAAP operating margin was 16.2%, while adjusted margin was 19.3%. TTM FCF was about $294 million and SBC $78 million. The model assumes meaningful further scale but includes compensation and ongoing manufacturing investment. Growth should be assessed against cash conversion and product quality, not only adjusted EPS.

Financial direction: Mixed — assess the reported trend alongside dilution and the balance sheet.

Current Valuation

Metric	Value
Price Snapshot	$154.86 — 2026-11-03 regular-session close, America/New_York
Market Capitalization	$9.89B
Enterprise Value	$10.31B
Trailing P/E	26.93
Provider forward P/E	20.66
EV / Sales	3.38

Comparable Company Analysis

Company	Relevance	Public / Private	Forward P/E	EV / Sales	Growth / Margin / Risk Context
PODD — Insulet Corporation	Subject company	Public	20.66	3.38	automated insulin delivery; 3Y revenue-growth estimate 15.98%; operating margin 16.89%
BBNX — Beta Bionics	Direct iLet AID competitor	Public	n/a	6.50	automated insulin delivery; 3Y revenue-growth estimate 39.09%; operating margin -69.75%
TNDM — Tandem	Direct pump/AID competitor	Public	n/a	1.38	insulin pump systems; 3Y revenue-growth estimate 10.27%; operating margin -4.13%
MiniMed (MMED)	Direct: MiniMed automated insulin-delivery systems	Public	N/D — no matched snapshot collected	N/D — no matched snapshot collected	Competes for AID patients
Multiple daily injections	Substitute: insulin pens/syringes, often with CGM	Operating alternative / no standalone security	N/D — no matched snapshot collected	N/D — no matched snapshot collected	Patient preference and access affect substitution

Comparable takeaway: Pump/AID systems and injections are the relevant alternatives. Dexcom supplies complementary glucose data and is not a pump competitor. Use independent MiniMed rather than the former Medtronic parent after separation. Quoted multiples retain their original dated snapshot; missing matched multiples are not estimated. Consolidated parent multiples do not isolate the competing product. No mechanical peer average is used.

The base terminal P/E is 28×, versus the provider's current forward P/E of 20.66×. Holding that quoted multiple constant on this model's 2029 EPS gives an illustrative present value of $117.64, versus the central base FV of $159.44. Earnings definitions differ, so this is a sensitivity check; it makes the dependence on a rerating or derating explicit.

Valuation Scenarios

Scenario	Key Assumptions	Fair Value	Probability	Probability Rationale	Return From Price Snapshot
Bear	3Y revenue CAGR 10%; sustainable 2029 EPS $4.50 after compensation; 18× P/E; 12% discount rate; Slower adoption and continued costs produce $4.50 of 2029 sustainable EPS.	$57.65	25%	Execution, financing or competitive setbacks remain credible	-62.8%
Base	3Y revenue CAGR 18%; sustainable 2029 EPS $8.00 after compensation; 28× P/E; 12% discount rate; The central revenue and margin trajectory produces $8.00 of 2029 sustainable EPS.	$159.44	50%	Most likely operating trajectory, requiring measurable progress	+3.0%
Bull	3Y revenue CAGR 25%; sustainable 2029 EPS $12.00 after compensation; 34× P/E; 12% discount rate; Strong adoption and mature margins produce $12.00 of 2029 sustainable EPS.	$290.41	25%	Successful product conversion and operating leverage; not assured	+87.5%
Probability-Weighted	Sum of each scenario value × its probability	$166.74	100%	Judgmental scenario probabilities	+7.7%

Valuation Takeaway

• Primary valuation method: Present value of sustainable 2029 equity earnings × scenario P/E, plus assumed interim dividends. The three-year discount horizon approximates late-2029 earning power.
• Cross-check methods: Direct competition, quoted peer multiples, current cash conversion, and the separate revenue/share/net-margin bridge in the valuation workpaper.
• Key valuation dependencies: New-patient starts and retention; Reimbursement, competition and product reliability; Manufacturing scale and cash conversion. All forward figures are independent research assumptions, not company guidance or consensus.
• Valuation confidence / Risk Level: 55/100 / Medium-High. Scenario values are sensitive to sustainable earnings and terminal multiples.
• Margin-of-safety conclusion: Hold / Watch at $142.64. New-file boundaries use Strong Buy = min(P/W FV ÷ 1.5, 1.1 × bear FV), Buy upper = P/W FV ÷ 1.25, Avoid above = P/W FV ÷ 0.90. Returns are to present fair value, not annualized returns or price targets for a particular date.

Management has expanded adoption and international reach. Capital allocation should prioritize manufacturing reliability, patient experience and profitable access. Monitor capacity investment, quality events and the consistency of new-product execution. Management has not yet demonstrated that Type 2 service interventions restore retention. Guidance excludes an assumed recovery, which is sensible, but the durability of the addressable expansion needs new cohort evidence.

Management Takeaway

Guidance excludes an assumed recovery, which is sensible, but the durability of the addressable expansion needs new cohort evidence.

Analyzed call: Q2 2026, complete material Q&A · Research snapshot: 2026-10-21

The table consolidates related questions and follow-ups from each material participant in the complete call.

Analyst / Firm	Core Question	Management Response	Research Read-Through
Robbie Marcus / J.P. Morgan	How does deterioration in Type 2 retention affect guidance?	Management said guidance assumes the retention pressure persists.	Confirm that this opportunity converts into profitable recurring demand.
Travis Steed / Bank of America	What supports confidence in the reduced outlook?	Management said diversified growth supports that outlook.	Treat the stated timetable as conditional on demonstrated execution.
Larry Biegelsen / Wells Fargo	What matters most to improving retention?	Management emphasized early patient support and primary-care access.	Check repeat usage and cohort economics rather than initial sales alone.
Jeff Johnson / Baird	How do adherence initiatives interact with payer access?	Management said it is not pursuing an exclusionary access strategy.	Confirm that this opportunity converts into profitable recurring demand.
Matt Taylor / Jefferies	What evidence supports the retention initiatives?	Management said early evidence is encouraging but does not establish broad improvement.	Check repeat usage and cohort economics rather than initial sales alone.
Marie Thibault / BTIG	Does guidance assume a recovery in retention despite competition?	Management said guidance does not assume a retention recovery.	Treat the stated timetable as conditional on demonstrated execution.
Richard Newitter / Truist Securities	When could the interventions affect results?	Management said second-half assumptions remain cautious.	Treat the stated timetable as conditional on demonstrated execution.
Joe Federico / Stifel	How do acquisition and service initiatives affect costs?	Management said the initiatives fit within the existing cost baseline.	Require durable cash conversion after compensation and ongoing investment.
Kieran Ryan / Deutsche Bank	Is retention or utilization the larger source of variance?	Management said retention is the larger source of variance.	Check repeat usage and cohort economics rather than initial sales alone.

Analyst-Q&A Takeaway

Type 2 retention is the central admission, and guidance assumes it does not recover this year. Patient-support initiatives need measured cohort improvement before the broader addressable market deserves full credit.

Source	Type	Date / Period	What It Supports
Insulet Corporation - Insulet Reports Second Quarter 2026 Results	Company IR / earnings filing	Q2 2026	Latest operating results, guidance, products and financial supplement
PODD complete earnings-call transcript	Transcript	Q2 2026	Prepared remarks and all material Q&A exchanges
PODD regular-session historical price	Market data	2026-10-20 close	Common price used in returns, scores and zones
PODD valuation statistics	Market data	2026-10-20 close; ratios retrieved 2026-10-21	Market capitalization, shares, quoted multiples and current ratios
PODD historical income statement	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical income statement; source-native currency and definitions
PODD historical balance sheet	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical balance sheet; source-native currency and definitions
PODD historical cash flows	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical cash flows; source-native currency and definitions
Beta Bionics statistics	Comparable-company market data	2026-10-20 regular close	Peer multiples and financial context; public quote basis
Tandem statistics	Comparable-company market data	2026-10-20 regular close	Peer multiples and financial context; public quote basis
MiniMed separation prospectus — standalone products and competition	Regulatory filing / primary product evidence	2026 separation prospectus; checked 2026-10-28	Independent MiniMed, AID systems and separation from Medtronic
SEC XBRL company facts — PODD	Regulatory filing (as tagged)	FY2026, through 2026-09-30	Current-year standalone-quarter and year-to-date source facts for FCF, SBC, revenue and other reported metrics

Research context

• Company: Insulet Corporation

• Ticker: PODD

• Exchange: Nasdaq

• Sector / Industry: Health Care / automated insulin delivery

• Template version: 2.7

• Research date: 2026-10-21

• Valuation / score price snapshot: $154.86 — 2026-11-03 regular-session close, America/New_York

• Tracking tier: Primary Watchlist

• Owned: No

• Primary operating period reviewed: Q2 2026

• Historical period reviewed: TTM, FY 2025, FY 2024; latest balance-sheet date shown below

• Latest investor presentation reviewed: Results release and associated financial tables; no separate slide deck materially used

• Latest earnings call reviewed: Q2 2026, complete material Q&A

• Latest post-earnings management commentary reviewed: No separate later management presentation incorporated

• Price snapshot date: 2026-11-03

• Price snapshot time / timezone: Regular-session close, America/New_York (including exchange half-days)

• Competitor / analyst-Q&A audit: 2026-10-28; original operating, price and valuation snapshots retained.

PODD — Insulet Corporation

Company & Research Metadata

• Company: Insulet Corporation

• Ticker: PODD

• Exchange: Nasdaq

• Sector / Industry: Health Care / automated insulin delivery

• Template version: 2.7

• Research date: 2026-10-21

• Valuation / score price snapshot: $154.86 — 2026-11-03 regular-session close, America/New_York

• Tracking tier: Primary Watchlist

• Owned: No

• Primary operating period reviewed: Q2 2026

• Historical period reviewed: TTM, FY 2025, FY 2024; latest balance-sheet date shown below

• Latest investor presentation reviewed: Results release and associated financial tables; no separate slide deck materially used

• Latest earnings call reviewed: Q2 2026, complete material Q&A

• Latest post-earnings management commentary reviewed: No separate later management presentation incorporated

• Price snapshot date: 2026-11-03

• Price snapshot time / timezone: Regular-session close, America/New_York (including exchange half-days)

• Competitor / analyst-Q&A audit: 2026-10-28; original operating, price and valuation snapshots retained.

What's Changed Since Previous Review

Current Review: 2026-10-28

Previous Review: 2026-10-21

Update Trigger: Competitor relevance and analyst-Q&A correction

Area	Previous View	Current View	Investment Impact
Competition	Preceding operating and comparable-company classifications	Product/customer/geographic boundaries corrected; direct rivals separated from substitutes, partners and valuation anchors	Corrects the competitive comparison; does not by itself re-underwrite the valuation
Analyst questions	Prior source-linked Q&A summaries	Complete questions and sentence-form management answers; all 9 existing rows retained	Improves readability while preserving the recorded exchange meaning
Valuation and scores	Approved operating/price snapshots, scenarios, scores and decisions	Preserved	No price refresh, rerank or change to valuation assumptions in this correction pass

Thesis: No new fundamental thesis determination is made in this correction pass. The prior investment decision is preserved; the corrected competitive scope should govern the next substantive review.

Investment Snapshot

Metric	Current View
Price Snapshot	$154.86 — 2026-11-03 regular-session close, America/New_York
Rating / Zone Status	Hold / Watch
Bear / Base / Bull Fair Value	$57.65 / $159.44 / $290.41
Scenario Probabilities	25% / 50% / 25%
Probability-Weighted Fair Value	$166.74
Probability-Weighted Expected Return	+7.7%
Bear-Case Return	-62.8%
Strong Buy Zone	≤ $63.42
Buy Zone	>$63.42–$133.39
Avoid Chasing Above	> $185.27
Quality Score / Tier	83.4 / Tier A
Opportunity Score / Rank	56.1 / #34 of 76
Risk Level	Medium-High
Tracking / Ownership	Primary Watchlist / Not Owned

Decision rationale: PODD is Hold / Watch at $142.64, with +16.9% probability-weighted upside and -59.6% bear-case return. A recurring consumable model and expanding automated-delivery adoption can support durable per-share growth. Confidence is 55/100 because the earnings conversion, competitive and capital assumptions below remain conditional.

Investment Thesis

A recurring consumable model and expanding automated-delivery adoption can support durable per-share growth. Q2 revenue rose 23.5% to $801.7 million, including strong international growth. The key question is whether new-patient adoption, retention and manufacturing scale sustain attractive margins as competition increases. The lower market valuation improves the entry case, provided the operating thesis remains intact. The latest call exposed weaker Type 2 retention, rather than merely slightly lower utilization. Management's revised guidance assumes those trends persist through the second half. Faster new-patient starts cannot compensate indefinitely for patients leaving treatment.

What the Market May Be Mispricing

Debate	Research judgment
New-patient starts and retention	A recurring consumable model and expanding automated-delivery adoption can support durable per-share growth.
Reimbursement, competition and product reliability	New-patient starts, retention, pods per active user, reimbursement and manufacturing yields determine lifetime value.
Manufacturing scale and cash conversion	Q2 GAAP operating margin was 16.2%, while adjusted margin was 19.3%.

Business Overview

Insulet sells Omnipod tubeless insulin-delivery systems, with recurring disposable pods supporting revenue after a patient adopts the platform. Automated delivery integrates with compatible glucose-monitoring technology and software. Pharmacy distribution, reimbursement, clinical support and patient training shape access. U.S. and international adoption have different pricing and reimbursement economics.

Business Takeaway

Insulet sells Omnipod tubeless insulin-delivery systems, with recurring disposable pods supporting revenue after a patient adopts the platform. New-patient starts, retention, pods per active user, reimbursement and manufacturing yields determine lifetime value.

Industry, TAM & Market Share

Insulin-treated diabetes provides a meaningful runway, including patients who have not used pumps. Clinical eligibility, reimbursement, patient preference and training constrain the economically reachable market. Competing delivery systems and improving therapies can change adoption, but should be evaluated using actual patient and clinical evidence.

Market-Share Analysis

Comparable same-definition share data for the subject and its principal rivals were not established. TAM estimates and company-specific volume measures are not treated as directly comparable market shares. The positioning analysis below is more reliable than a table of unmatched percentages.

Competitive Scale / Position

Company / Platform	Primary Position	Relative Scale	Growth Direction	Investment Relevance
Tandem (TNDM)	Direct: insulin pumps and automated insulin delivery	Product scope; no matched operating-scale series	Competes for pump starts and renewals	Customer choice in the stated segment only
Beta Bionics (BBNX)	Direct: iLet automated insulin delivery	Product scope; no matched operating-scale series	Competes for AID patient adoption	Customer choice in the stated segment only
MiniMed (MMED)	Direct: MiniMed automated insulin-delivery systems	Product scope; no matched operating-scale series	Competes for AID patients	Customer choice in the stated segment only
Multiple daily injections	Substitute: insulin pens/syringes, often with CGM	Product scope; no matched operating-scale series	Patient preference and access affect substitution	Customer choice in the stated segment only

Industry Takeaway

Competing delivery systems and improving therapies can change adoption, but should be evaluated using actual patient and clinical evidence. The base case requires evidence of profitable adoption within that market.

Customer Economics

New-patient starts, retention, pods per active user, reimbursement and manufacturing yields determine lifetime value. Recurring consumables produce attractive visibility after adoption. Customer service, acquisition spending and geographic mix must be included when evaluating incremental margins.

Customer-Economics Takeaway

The economic test is Manufacturing scale and cash conversion. Customer service, acquisition spending and geographic mix must be included when evaluating incremental margins.

Competitive Landscape & Moat

Competitive Landscape

Pump/AID systems and injections are the relevant alternatives. Dexcom supplies complementary glucose data and is not a pump competitor. Use independent MiniMed rather than the former Medtronic parent after separation.

Competitor	Market Share	Positioning	Advantages vs. Company	Disadvantages vs. Company	Current Direction
Tandem (TNDM)	No consistent comparable series	Direct: insulin pumps and automated insulin delivery	Established pump/algorithm ecosystem	Tubed/tubeless workflows and distribution differ	Competes for pump starts and renewals
Beta Bionics (BBNX)	No consistent comparable series	Direct: iLet automated insulin delivery	Distinct automation proposition	Different device workflow and commercial scale	Competes for AID patient adoption
MiniMed (MMED)	No consistent comparable series	Direct: MiniMed automated insulin-delivery systems	Pump, sensor and consumables ecosystem	Independent after Medtronic separation; distinct tubed workflow	Competes for AID patients
Multiple daily injections	No consistent comparable series	Substitute: insulin pens/syringes, often with CGM	Familiar treatment and no pump attachment	Does not provide the same automated delivery workflow	Patient preference and access affect substitution

Moat Assessment

Tubeless design, regulatory approvals, patient familiarity, distribution and integration create strong switching costs and differentiation. Competition can still improve convenience or pricing. The moat depends on maintaining reliability and patient outcomes.

Moat direction: Stable — an analytical judgment about product and distribution economics, not a measured market-share claim.

Competitive Takeaway

Tubeless design, regulatory approvals, patient familiarity, distribution and integration create strong switching costs and differentiation. The direct rivals determine commercial pressure; diversified or sector anchors provide valuation context and are not substitutes for direct competition.

Financial Profile

Historical Financials

Financial reporting periods follow the issuer's fiscal year: completed FY rows plus standalone current-year quarters and cumulative H1/9M for FY2026. Revenue, FCF and SBC are flows; cash is a period-end balance. FCF = operating cash flow minus property/equipment capex from SEC company facts; quarterly FCF after Q1 and any quarterly SBC derived from YTD are visibly marked. Missing values are N/D, not zero. Unit: USD millions. Data extracted from SEC-tagged filings as of 2026-11-07. Company-specific FCF definitions and acquisition effects may require further reconciliation.

Period	Revenue	Growth	Gross Margin	Operating Margin	FCF	FCF Margin	SBC	Diluted Shares	Cash	Debt
FY2024	2,072	22.07%	69.79%	14.91%	305.3	14.74%	69.3	74	958.8	1,434
FY2025	2,708	30.73%	71.63%	17.50%	377.7	13.95%	62.7	72	716.1	1,003
Q1 FY2026	$761.7	N/D	69.5%	16.0%	$89.5 (derived: CFO - capex)	11.8%	$21.3	70.202	N/D	N/D
Q2 FY2026	$801.7	N/D	70.2%	16.2%	$55.9 (derived: current YTD - prior YTD)	7.0%	$19.6 (derived: current YTD - prior YTD)	69.403	N/D	N/D
H1 FY2026	$1,563.4	N/D	69.8%	16.1%	$145.4 (derived: CFO - capex)	9.3%	$40.9	69.803	N/D	N/D
Q3 FY2026	$842	N/D	75.1%	22.5%	$66.4 (derived: current YTD - prior YTD)	7.9%	$20.6 (derived: current YTD - prior YTD)	69.492	N/D	N/D
9M FY2026	$2,405.4	N/D	71.7%	18.4%	$211.8 (derived: CFO - capex)	8.8%	$61.5	69.699	N/D	N/D

Financial Takeaways

Q2 GAAP operating margin was 16.2%, while adjusted margin was 19.3%. TTM FCF was about $294 million and SBC $78 million. The model assumes meaningful further scale but includes compensation and ongoing manufacturing investment. Growth should be assessed against cash conversion and product quality, not only adjusted EPS.

Financial direction: Mixed — assess the reported trend alongside dilution and the balance sheet.

Management & Capital Allocation

Management has expanded adoption and international reach. Capital allocation should prioritize manufacturing reliability, patient experience and profitable access. Monitor capacity investment, quality events and the consistency of new-product execution. Management has not yet demonstrated that Type 2 service interventions restore retention. Guidance excludes an assumed recovery, which is sensible, but the durability of the addressable expansion needs new cohort evidence.

Management Takeaway

Guidance excludes an assumed recovery, which is sensible, but the durability of the addressable expansion needs new cohort evidence.

Valuation

Current Valuation

Metric	Value
Price Snapshot	$154.86 — 2026-11-03 regular-session close, America/New_York
Market Capitalization	$9.89B
Enterprise Value	$10.31B
Trailing P/E	26.93
Provider forward P/E	20.66
EV / Sales	3.38

Comparable Company Analysis

Company	Relevance	Public / Private	Forward P/E	EV / Sales	Growth / Margin / Risk Context
PODD — Insulet Corporation	Subject company	Public	20.66	3.38	automated insulin delivery; 3Y revenue-growth estimate 15.98%; operating margin 16.89%
BBNX — Beta Bionics	Direct iLet AID competitor	Public	n/a	6.50	automated insulin delivery; 3Y revenue-growth estimate 39.09%; operating margin -69.75%
TNDM — Tandem	Direct pump/AID competitor	Public	n/a	1.38	insulin pump systems; 3Y revenue-growth estimate 10.27%; operating margin -4.13%
MiniMed (MMED)	Direct: MiniMed automated insulin-delivery systems	Public	N/D — no matched snapshot collected	N/D — no matched snapshot collected	Competes for AID patients
Multiple daily injections	Substitute: insulin pens/syringes, often with CGM	Operating alternative / no standalone security	N/D — no matched snapshot collected	N/D — no matched snapshot collected	Patient preference and access affect substitution

Comparable takeaway: Pump/AID systems and injections are the relevant alternatives. Dexcom supplies complementary glucose data and is not a pump competitor. Use independent MiniMed rather than the former Medtronic parent after separation. Quoted multiples retain their original dated snapshot; missing matched multiples are not estimated. Consolidated parent multiples do not isolate the competing product. No mechanical peer average is used.

The base terminal P/E is 28×, versus the provider's current forward P/E of 20.66×. Holding that quoted multiple constant on this model's 2029 EPS gives an illustrative present value of $117.64, versus the central base FV of $159.44. Earnings definitions differ, so this is a sensitivity check; it makes the dependence on a rerating or derating explicit.

Valuation Scenarios

Scenario	Key Assumptions	Fair Value	Probability	Probability Rationale	Return From Price Snapshot
Bear	3Y revenue CAGR 10%; sustainable 2029 EPS $4.50 after compensation; 18× P/E; 12% discount rate; Slower adoption and continued costs produce $4.50 of 2029 sustainable EPS.	$57.65	25%	Execution, financing or competitive setbacks remain credible	-62.8%
Base	3Y revenue CAGR 18%; sustainable 2029 EPS $8.00 after compensation; 28× P/E; 12% discount rate; The central revenue and margin trajectory produces $8.00 of 2029 sustainable EPS.	$159.44	50%	Most likely operating trajectory, requiring measurable progress	+3.0%
Bull	3Y revenue CAGR 25%; sustainable 2029 EPS $12.00 after compensation; 34× P/E; 12% discount rate; Strong adoption and mature margins produce $12.00 of 2029 sustainable EPS.	$290.41	25%	Successful product conversion and operating leverage; not assured	+87.5%
Probability-Weighted	Sum of each scenario value × its probability	$166.74	100%	Judgmental scenario probabilities	+7.7%

Valuation Takeaway

• Primary valuation method: Present value of sustainable 2029 equity earnings × scenario P/E, plus assumed interim dividends. The three-year discount horizon approximates late-2029 earning power.
• Cross-check methods: Direct competition, quoted peer multiples, current cash conversion, and the separate revenue/share/net-margin bridge in the valuation workpaper.
• Key valuation dependencies: New-patient starts and retention; Reimbursement, competition and product reliability; Manufacturing scale and cash conversion. All forward figures are independent research assumptions, not company guidance or consensus.
• Valuation confidence / Risk Level: 55/100 / Medium-High. Scenario values are sensitive to sustainable earnings and terminal multiples.
• Margin-of-safety conclusion: Hold / Watch at $142.64. New-file boundaries use Strong Buy = min(P/W FV ÷ 1.5, 1.1 × bear FV), Buy upper = P/W FV ÷ 1.25, Avoid above = P/W FV ÷ 0.90. Returns are to present fair value, not annualized returns or price targets for a particular date.

Analyst Questions

The table consolidates related questions and follow-ups from each material participant in the complete call.

Analyst / Firm	Core Question	Management Response	Research Read-Through
Robbie Marcus / J.P. Morgan	How does deterioration in Type 2 retention affect guidance?	Management said guidance assumes the retention pressure persists.	Confirm that this opportunity converts into profitable recurring demand.
Travis Steed / Bank of America	What supports confidence in the reduced outlook?	Management said diversified growth supports that outlook.	Treat the stated timetable as conditional on demonstrated execution.
Larry Biegelsen / Wells Fargo	What matters most to improving retention?	Management emphasized early patient support and primary-care access.	Check repeat usage and cohort economics rather than initial sales alone.
Jeff Johnson / Baird	How do adherence initiatives interact with payer access?	Management said it is not pursuing an exclusionary access strategy.	Confirm that this opportunity converts into profitable recurring demand.
Matt Taylor / Jefferies	What evidence supports the retention initiatives?	Management said early evidence is encouraging but does not establish broad improvement.	Check repeat usage and cohort economics rather than initial sales alone.
Marie Thibault / BTIG	Does guidance assume a recovery in retention despite competition?	Management said guidance does not assume a retention recovery.	Treat the stated timetable as conditional on demonstrated execution.
Richard Newitter / Truist Securities	When could the interventions affect results?	Management said second-half assumptions remain cautious.	Treat the stated timetable as conditional on demonstrated execution.
Joe Federico / Stifel	How do acquisition and service initiatives affect costs?	Management said the initiatives fit within the existing cost baseline.	Require durable cash conversion after compensation and ongoing investment.
Kieran Ryan / Deutsche Bank	Is retention or utilization the larger source of variance?	Management said retention is the larger source of variance.	Check repeat usage and cohort economics rather than initial sales alone.

Analyst-Q&A Takeaway

Type 2 retention is the central admission, and guidance assumes it does not recover this year. Patient-support initiatives need measured cohort improvement before the broader addressable market deserves full credit.

Thesis Monitoring

Driver	Current State	Positive Trigger / Catalyst	Negative Trigger / Falsifier	What It Changes
New-patient starts and retention	A recurring consumable model and expanding automated-delivery adoption can support durable per-share growth.	Revenue trajectory sustains approximately 18% annual growth on a comparable basis	Growth remains below the 10% bear assumption over a full operating cycle	Revenue outlook and scenario probabilities
Reimbursement, competition and product reliability	New-patient starts, retention, pods per active user, reimbursement and manufacturing yields determine lifetime value.	After-cost earnings progress toward the base implied net margin of 11.2%	Competition, credit losses or service costs make that margin trajectory unattainable	Margins, moat score and valuation multiple
Manufacturing scale and cash conversion	Q2 GAAP operating margin was 16.2%, while adjusted margin was 19.3%.	Financing and compensation remain consistent with 70.4M economic shares in the 2029 base case	Required capital or cumulative dilution materially exceeds the model without matching earnings	Financial score, confidence and downside value

Quality & Opportunity Scorecards

Quality Score

Component	Score	Weight	Weighted Contribution	Evidence
Business durability and economics	90	25%	22.5	New-patient starts, retention, pods per active user, reimbursement and manufacturing yields determine lifetime value.
Moat and competitive position	86	25%	21.5	Tubeless design, regulatory approvals, patient familiarity, distribution and integration create strong switching costs and differentiation.
Growth runway and durability	82	20%	16.4	Insulin-treated diabetes provides a meaningful runway, including patients who have not used pumps.
Financial quality and balance sheet	79	15%	11.9	Q2 GAAP operating margin was 16.2%, while adjusted margin was 19.3%.
Management, governance and capital allocation	74	15%	11.1	Management has expanded adoption and international reach.
Quality Score	83.4	100%	83.4	Weighted score, independent of ownership and current price

• Quality Tier: A
• Speculative override: None

Opportunity Score

Component	Raw Input	Normalized Score	Weight	Weighted Contribution
Quality	83.4	83.4	30%	25.0
Probability-weighted upside	+7.7%	65.3	35%	22.9
Bear-case downside	-62.8%	0.0	20%	0.0
Risk / valuation confidence	55	55.0	15%	8.3
Opportunity Score		56.1	100%	56.1

• Opportunity Rank: #34 of 76
• Zone Status: Hold / Watch

Portfolio Context

• Tracking tier: Primary Watchlist
• Owned: No
• Tracking source of truth: my_watchlist.md
• Portfolio source of truth: portfolio/holdings.md
• Scoring independence: Ownership, account, shares, position size and cost basis do not change research, valuation, Quality, Opportunity, rank or zones.

Investment Decision History

Timestamp	Price	Rating	Zone Status	Buy Zone	Strong Buy Zone	Avoid Chasing Above	Base FV	P/W FV	P/W Return	Quality	Opportunity / Rank	Change / Rationale
2026-10-21 (America/New_York)	$142.64	Hold / Watch	Hold / Watch	>$63.42–$133.39	≤ $63.42	> $185.27	$159.44	$166.74	+16.9%	83.4	62.6 / #18	Initial missing-file analysis; common-universe ranking; independent scenario assumptions

---

Material Sources

Source	Type	Date / Period	What It Supports
Insulet Corporation - Insulet Reports Second Quarter 2026 Results	Company IR / earnings filing	Q2 2026	Latest operating results, guidance, products and financial supplement
PODD complete earnings-call transcript	Transcript	Q2 2026	Prepared remarks and all material Q&A exchanges
PODD regular-session historical price	Market data	2026-10-20 close	Common price used in returns, scores and zones
PODD valuation statistics	Market data	2026-10-20 close; ratios retrieved 2026-10-21	Market capitalization, shares, quoted multiples and current ratios
PODD historical income statement	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical income statement; source-native currency and definitions
PODD historical balance sheet	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical balance sheet; source-native currency and definitions
PODD historical cash flows	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical cash flows; source-native currency and definitions
Beta Bionics statistics	Comparable-company market data	2026-10-20 regular close	Peer multiples and financial context; public quote basis
Tandem statistics	Comparable-company market data	2026-10-20 regular close	Peer multiples and financial context; public quote basis
MiniMed separation prospectus — standalone products and competition	Regulatory filing / primary product evidence	2026 separation prospectus; checked 2026-10-28	Independent MiniMed, AID systems and separation from Medtronic
SEC XBRL company facts — PODD	Regulatory filing (as tagged)	FY2026, through 2026-09-30	Current-year standalone-quarter and year-to-date source facts for FCF, SBC, revenue and other reported metrics